Search or
𝛼SK
𝛼SKSign in with Google. Opens in new tab
bullish
Cipla Ltd - Promising Pipeline, Maintain BUY
The company’s US revenue stood at $226 Mn, reflecting a 9.6% YoY decline impacted by gRevlimid and a 2.3% increase QoQ on improved lanreotide sales.
What is covered in the Full Insight:
- Recommendation Rationale
- Cipla's Quarterly Performance
- Financial Outlook
- Key Risks
- Company Outlook & Recommendation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 14-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Nikkei 225 Index Rebalance: 🚨Ibiden (4062 JP) To Replace Nidec (6594 JP) 🚨
- [Japan Special] Ibiden (4062) Replaces Nidec (6594) In Nikkei 225 on Accounting - A VERY BIG DEAL
- Taiwan Dual-Listings Monitor: TSMC Near Fresh Spread Short Level; ChipMOS Rare Discount
- IDX30/LQ45/IDX80 Index Rebalance: Plenty of Change with 4 Days to Trade
- [Japan Offering] Kasumigaseki Capital (3498 JP) - BIG Primary for Big Plans
Top Unpaywalled Insights
More »- Curator's Cut: Japan's Defense Drive, Asia's Vision Opportunities & US Diagnostics Picks
- Overview #38 Precious Metals – Has the Fat Lady Sung?
- VEON (VEON US) 3Q25 Preview: Digital Revenue Mix & Margins Expanding
- Nvidia (NVDA.US): Problems Encountered in Land Acquisition to Establish Offshore Headquarters.
- OV #37 – From Chips to Ships: Markets Rattle as Trade War Escalates
Discussions
(Paid Plans Only)
x